Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cilostazol Effects on Biomarkers in HD Patients with PAD
NCT00431249Phase 4Completed
- Sponsor
- 童綜合醫院
- Start
- Feb 2007
- Primary completion
- Apr 2008
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, single-blind trial of cilostazol in Peripheral Arterial Disease (PAD) (2 arms), sponsored by 童綜合醫院. Primary endpoints: Vascular Endothelial Growth Factor at 12 weeks, Tissue Factor at 12 weeks and 5 more. Started Feb 2007; status: completed.
02
Drugs
cilostazol
03
Conditions
Peripheral Arterial Disease (PAD)
Beyond the preview
Go deeper on NCT00431249.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00431249.